NEW YORK (GenomeWeb) – QuantuMDx and The Global Good Fund have announced a co-development and commercialization agreement for a point-of-care diagnostics platform and assay to detect 13 high-risk oncotypes of the human papillomavirus. The collaboration is aimed at providing an easy-to-use molecular test that can be deployed to remote cervical cancer screening programs in low-resources settings.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.